PATENT CLAIM ANALYSIS

Application Number: 16207655
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["424", "144100"]

Abstract:
The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.

Claim (Index 84):
The method of  claim 78 , wherein the anti-TNF-\u03b1 antibody or antibody fragment consists of at least 92% sequence identity to the amino acid sequence set forth in any one of SEQ ID NOS: 90-91 or a combination thereof.

Metadata:
- Claim Count in Document: 77.0
- Percentile: 98.0
- Lexical Diversity: 1.39535
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16207637', '16207611', '15309177', '15616140', '13822435']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.760358437243108
- 35 USC 102 Novelty (BERT): 0.5780649422145187
- Combined Prediction Score: 0.7421290877402491
- Mean Citation Score: 428.853182
- Max Citation Score: 500.5607
- Similarity Product: 381.0129067781985

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test